©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 105085
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105085
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.105085
Prognostic value of post-neoadjuvant immunochemotherapy hypercoagulation in gastric cancer patients undergoing surgery
Meng-Jie Quan, Qiang Lin, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China
Author contributions: Quan MJ wrote the manuscript; Lin Q conceived and designed the study, and revised the manuscript. All authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare that there is no conflict of interest.
Corresponding author: Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, No. 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com
Received: January 15, 2025
Revised: April 1, 2025
Accepted: April 10, 2025
Published online: June 15, 2025
Processing time: 150 Days and 3.7 Hours
Revised: April 1, 2025
Accepted: April 10, 2025
Published online: June 15, 2025
Processing time: 150 Days and 3.7 Hours
Core Tip
Core Tip: The prognosis of patients with locally advanced gastric cancer undergoing neoadjuvant immunochemotherapy (NICT) plus radical surgery varies. Post-NICT hypercoagulation may act as a prognostic indicator. However, standardized methods for assessing cancer-associated hypercoagulation are lacking. Future research should concentrate on identifying more precise and efficient biomarkers for assessing cancer-associated hypercoagulation to refine prognostic evaluation and guide individualized treatment.